Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up - Still a Buy?

Key Points

• Ascentage Pharma shares jumped: The stock opened at $18.42 versus a prior close of $16.90 and last traded near $18.28, though trading volume was modest.
• Analysts remain bullish: The stock has a consensus “Buy” rating, with two analysts issuing “Strong Buy” ratings and eight assigning “Buy” ratings. The average price target is $46.43, substantially above its current price.
• Financial results remain unprofitable: Ascentage reported a quarterly loss of $0.65 per share on $22.24 million in revenue, while analysts expect a full-year loss of $2.26 per share. Institutional investors including UBS, HSBC, and Citadel have recently increased or initiated positions.

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $16.90, but opened at $18.42. Ascentage Pharma Group International shares last traded at $18.2810, with a volume of 3,583 shares.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. B. Riley Financial started coverage on Ascentage Pharma Group International in a research note on Wednesday, June 10th. They issued a "buy" rating and a $45.00 price target on the stock. BTIG Research reiterated a "buy" rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Friday, August 21st. Finally, Raymond James Financial reiterated a "buy" rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. Two investment analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $46.43.

Ascentage Pharma Group International Price Performance

The firm's 50-day moving average is $18.18 and its 200-day moving average is $21.04. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.22 and a quick ratio of 1.18.

Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report) last announced its quarterly earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The business had revenue of $22.24 million for the quarter. On average, sell-side analysts expect that Ascentage Pharma Group International - Unsponsored ADR will post -2.26 earnings per share for the current year.

Institutional Investors Weigh In On Ascentage Pharma Group International

Several hedge funds and other institutional investors have recently made changes to their positions in the business. UBS Group AG lifted its position in Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company's stock valued at $716,000 after acquiring an additional 10,988 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International in the second quarter worth approximately $391,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Ascentage Pharma Group International in the third quarter worth approximately $383,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source